Medicaloid

PCSK9

FDA rebuffs Novartis’ cholesterol drug inclisiran in an ‘inspection-related’ approval delay

Medicaloid
Manufacturing inspection-related woes have derailed another FDA approval this year, this time for a drug at the center of a $9.7 billion acquisition. Novartis’ cholesterol drug inclisiran...